FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 12/2023”. The Monitor is a month-to-month printed overview of enterprise capital tendencies within the European Life Sciences sector.
As of the top of December 2023 we determine the next present VC tendencies in Europe:
- In 2023, general Life Sciences funding has reached EUR 8,949m
- Biotech obtained 42% of the full funding quantity (+1% in comparison with the earlier month)
- Oncology dominates as the highest indication in Biotech
- Freya Biosciences (Denmark) has the very best transaction quantity of EUR 35m in December, adopted by Laza Medical (Switzerland) EUR 33m and Eligo Biosciences (France) EUR 30m
- The EIC Fund (car of the European Innovation Council, Belgium) dominates the High 5 Buyers (by deal quantity), adopted by Jeito (France) and Forbion (Netherlands)
- High 5 Offers exceed EUR 130m every, largest transaction amounted to EUR 683m in YgEia3 (United Kingdom)
To entry the complete report, please click on right here.
By Mathias Klozenbücher, Johannes Hyperlink and Marco Buonafede-Bennardo.